Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Surgical Oncology|February 24, 2006
Radical excision of malignant sacral tumors using a modified threadwire sawShunzo Osaka, Osamu Kondoh, Yukihiro Yoshida, et al.
Oncology Reports|December 27, 2021
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumorsNobuyuki Ishikura, Masamichi Sugimoto, Keigo Yorozu, et al.
The Journal of Biological Chemistry|August 31, 2002
Differential sensitivity between Fks1p and Fks2p against a novel beta -1,3-glucan synthase inhibitor, aerothricin3 [corrected]Osamu Kondoh, Tsuyoshi Takasuka, Mikio Arisawa, et al.
Cancer Letters|June 3, 2014
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceTatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida, et al.
Cancer Chemotherapy and Pharmacology|September 11, 2014
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesTatsushi Kodama, Masami Hasegawa, Kenji Takanashi, et al.
Cancer Diagnosis & Prognosis|September 5, 2022
Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB KnockoutNobuyuki Ishikura, Masamichi Sugimoto, Keigo Yorozu, et al.
Molecular Cancer Therapeutics|September 23, 2021
Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by ImmunotherapyToshiki Iwai, Masamichi Sugimoto, Hina Patel, et al.
Molecular Cancer Therapeutics|October 29, 2014
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancerTatsushi Kodama, Toshiyuki Tsukaguchi, Yasuko Satoh, et al.
Clinical & Experimental Metastasis|November 19, 2021
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusionChinami Masuda, Mamiko Morinaga, Daiko Wakita, et al.
Molecular Biology Reports|February 26, 2022
Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapiesNatsumi Kawasaki, Yoriko Yamashita-Kashima, Takaaki Fujimura, et al.
Pageof 3